Political risks cloud Pfizer's attractive valuation despite strong dividend yield.

Pfizer Inc. currently holds a buy rating on Wall Street, but concerns about political uncertainties involving drug pricing models like 'TrumpRx' and 'Most-Favored-Nation' pose risks to its profit margins and valuation. Although Pfizer's forward price-to-earnings ratio of 9.3 appears appealing, potential multi-year earnings declines temper this view. The company’s well-covered 6.27% dividend yield and progress in its drug pipeline provide some positive offsets to these challenges. Investors should weigh these factors carefully when considering Pfizer's stock.